Pharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?

Table 1

Schematic catalogue of SNPs commonly associated with T2D.

Chr	Position	Localization	Gene	Alleles	SNP ID	Protein change	Association
6	160543148; 160560824; 160560881; 160575837	Exon; Exon; Exon; Exon	SLC22A1	C/T; A/G; –/A; A/C/G	rs12208357; rs34130495; rs35167514; rs34059508	R61C; G401S; 420del; G465R	Metformin metabolism; T2D susceptibility
6	160670282	Exon	SLC22A2	G/T	rs316019	S270A	Metformin metabolism; T2D development
11	17409572; 17408630	Exon; Exon	KCNJ11	T/C; G/A	rs5219; rs5215	K23E; A250I	Sulphonylureas metabolism; T2D onset
10	96702047; 96741053	Exon; Exon	CYP2C9	C/T; A/C	rs1799853; rs1057910	R144C; I359L	Sulphonylureas metabolism; T2D susceptibility
11	17418477	Exon	ABCC8	G/T	rs757110	A1369S	Sulphonylureas metabolism; T2D onset
3	12393125	Exon	PPARG	C/G	rs1801282	P12A	TZD metabolism; T2D onset-; development
10	114808902; 114758349	Intron; Intron	TCF7L2	G/T; C/T	rs12255372; rs7903146	—; —	Sulphonylureas metabolism; T2D development
2	227093745; 227660544	Intergene; Exon	IRS1	C/T; G/A	rs2943641; rs1801278	—; G971R	Sulphonylureas treatment; T2D onset
2	241534293; 241531174; 241542703	Intron; Intron; Intron	CAPN10	Indel; A/G; C/T	rs3842570; rs3792267; rs5030952	—; —; —	Probably involved in Sulphonylureas response